Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Prothena Corporation PLC – Linkedin
Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases. Fueled by its deep scientific understanding built over decades of neuroscience research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab – PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, Aβ (Amyloid beta) and TDP-43 where its scientific understanding of disease pathology can be leveraged.
myBinderRelated Content
-
International Society of Amyloidosis (ISA)International Society of Amyloidosis (IS...
-
Multidisciplinary Cardiac Amyloidosis Center at University of Pittsburgh and University of Pittsburgh Medical CenterThe multi-disciplinary Cardiac Amyloidos...
-
Françoise PelcotFrançoise Pelcot is the Director of Ass...
-
Alnylam Clinical Trial Update – ASG Webinar 4/11https://www.youtube.com/watch?v=K2TmwAfu...
-
Deborah Boedicker, MBADeborah Boedicker is an active philanthr...
-
Cardiac Amyloidosis: On the Road in South Florida – CANCELEDAs part of an ongoing effort to expand a...
-
Utah Amyloidosis SymposiumOn behalf of the Organizing Committee, i...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
